Nilotinib

Advanced Malignant Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

123 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Nivolumab National Cancer Institute (NCI)	Phase 2	BB
Olaparib National Cancer Institute (NCI)	Phase 2	BB
Palbociclib National Cancer Institute (NCI)	Phase 2	BB
Vinorelbine OHSU Knight Cancer Institute	Phase 2	B
Carboplatin OHSU Knight Cancer Institute	Phase 2	B

View all 50 →

Same molecule, other indications

Nilotinib is also rated in:

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BBB

Indicative ·

74 / 100

chronic myeloid leukemiaDormant

BBB

Indicative ·

73 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.